Evommune, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EVMN research report →
Range $8 – $50
Price Chart
About the company
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases.
- CEO
- Luis C. Pena
- IPO
- 2025
- Employees
- 48
- HQ
- Palo Alto, CA, US
Get TickerSpark's AI analysis on EVMN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $291.10M
- P/E
- -1.85
- PEG
- 0.03
- P/S
- 0.00
- P/B
- 1.02
- EV/EBITDA
- -2.09
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -43.53%
- ROIC
- -49.89%
Latest fiscal year · YoY change
- Revenue
- $13.00M+85.7%
- Gross Profit
- $13.00M+127.6%
- Op Income
- $-81,071,000
- Net Income
- $-68,870,000-3.1%
- EPS
- $-11.22-394.3%
- OCF Growth
- -31.4%
- FCF Growth
- -31.6%
- 52W High
- $33.20
- 52W Low
- $4.94
- 50D MA
- $7.20
- 200D MA
- $16.92
- Beta
- 0.96
- RSI (14)
- 50
- Avg Volume
- 838.16K
No earnings-call transcripts are available for EVMN yet.
- Free Float
- 61.2%
- Shares Outstanding
- 41.35M
- Float Shares
- 25.29M
of shares held by institutions
116 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Eqt Fund Management S.A R.L. | 5.29M | 0 |
| Ra Capital Management, L.P. | 3.49M | 0 |
| Point72 Asset Management, L.P. | 2.43M | ▲ 999.03K |
| Pivotal Bioventure Partners Investment Advisor LLC | 1.93M | 0 |
| Nan Fung Group Holdings Ltd | 1.44M | 0 |
| Defilade Capital Management, L.P. | 1.43M | ▲ 637.43K |
| Vestal Point Capital, LP | 1.25M | ▲ 250.00K |
| Baker Bros. Advisors LP | 1.23M | ▲ 387.40K |
| Kynam Capital Management, LP | 1.20M | ▲ 1.20M |
| Blackrock, Inc. | 1.15M | ▲ 267.53K |
| Vanguard Capital Management LLC | 1.00M | ▲ 122.58K |
| Jupiter Topco LLC | 896.70K | ▲ 896.70K |
Held by 117 ETFs
Biggest fund positions in EVMN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 13, 26 | KIRSCH ARTHUR S | other | 37,960 |
| Nov 13, 26 | KIRSCH ARTHUR S | other | 15,673 |
| Nov 13, 26 | KIRSCH ARTHUR S | sell | 37,960 |
| Nov 13, 26 | KIRSCH ARTHUR S | sell | 15,673 |
| Nov 13, 26 | Cohen David E | other | 37,960 |
| Nov 13, 26 | Cohen David E | other | 15,673 |
| Nov 13, 26 | Cohen David E | sell | 15,673 |
| Nov 13, 26 | Cohen David E | sell | 37,960 |
| Nov 13, 26 | MCGRAW BENJAMIN F III | other | 37,960 |
| Nov 13, 26 | MCGRAW BENJAMIN F III | other | 15,673 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our EVMN coverage
Recent articles, reports, and earnings notes.
No research on EVMN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EVMN report →Evommune Reports Third Quarter 2026 Financial Results and Provides Business Highlights
businesswire.com · Nov 12
Evommune to Present at Upcoming Investor Conferences
businesswire.com · Nov 9
Evommune Licenses Experimental Arthritis Drug, Raises $30 Million to Fund Development
marketbeat.com · Nov 6
Evommune, Inc. (EVMN) Discusses In Licensing of EVO570 for Autoimmune Diseases Prepared Remarks Transcript
seekingalpha.com · Nov 6
Evommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET
businesswire.com · Nov 5
Evommune Announces $30 Million Private Placement
businesswire.com · Nov 4
Evommune Enters into Agreement to In-License EVO570, a Potential Best-in-Class Oral VAV1 Molecular Glue Degrader, from Hinova Pharmaceuticals
businesswire.com · Nov 4
Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress
businesswire.com · Oct 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.